BRIEF-Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1 Concentrations Are Closely Associated With Sepsis And Organ Failure

Reuters
12 Jun
BRIEF-Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1 Concentrations Are Closely Associated With Sepsis And Organ Failure

June 12 (Reuters) - VolitionRX Ltd VNRX.A:

  • VOLITION ANNOUNCES MARS CONSORTIUM CLINICAL STUDY SUGGESTS NU.Q® H3.1. CONCENTRATIONS ARE CLOSELY ASSOCIATED WITH SEPSIS AND ORGAN FAILURE

Source text: ID:nPnblsMN5a

Further company coverage: VNRX.A

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10